Page last updated: 2024-10-31

nafamostat and Flushing

nafamostat has been researched along with Flushing in 1 studies

nafamostat: inhibitor of trypsin, plasmin, pancreatic kallikrein, plasma kallikrein & thrombin; strongly inhibits esterolytic activities of C1r & C1 esterase complement-mediated hemolysis; antineoplastic

Flushing: A transient reddening of the face that may be due to fever, certain drugs, exertion, or stress.

Research Excerpts

ExcerptRelevanceReference
"For each of 10 patients with ulcerative colitis, we used four types of anticoagulants sequentially [NM (30-50 mg), heparin, low-molecular-weight heparin (LMWH) and NM (1 mg), and LMWH] for LCAP."2.73Selection of anticoagulants for leukocytapheresis therapy in cases of active ulcerative colitis. ( Hiraishi, H; Hoshino, M; Kanke, K; Nakano, M; Terano, A; Tominaga, K, 2007)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Kanke, K1
Hoshino, M1
Tominaga, K1
Nakano, M1
Terano, A1
Hiraishi, H1

Trials

1 trial available for nafamostat and Flushing

ArticleYear
Selection of anticoagulants for leukocytapheresis therapy in cases of active ulcerative colitis.
    Blood purification, 2007, Volume: 25, Issue:4

    Topics: Anticoagulants; Benzamidines; Biocompatible Materials; Biomarkers; Bradykinin; Colitis, Ulcerative;

2007